Molecular Endocrinology, Helmholtz Zentrum München (HMGU), German Center for Diabetes Research (DZD), Institute for Diabetes and Cancer IDC, Munich, Germany.
Department of Biology, Institute for Comparative Molecular Endocrinology, University of Ulm, Ulm, Germany.
Front Immunol. 2019 Aug 7;10:1859. doi: 10.3389/fimmu.2019.01859. eCollection 2019.
For many decades, glucocorticoids have been widely used as the gold standard treatment for inflammatory conditions. Unfortunately, their clinical use is limited by severe adverse effects such as insulin resistance, cardiometabolic diseases, muscle and skin atrophies, osteoporosis, and depression. Glucocorticoids exert their effects by binding to the Glucocorticoid Receptor (GR), a ligand-activated transcription factor which both positively, and negatively regulates gene expression. Extensive research during the past several years has uncovered novel mechanisms by which the GR activates and represses its target genes. Genome-wide studies and mouse models have provided valuable insight into the molecular mechanisms of inflammatory gene regulation by GR. This review focusses on newly identified target genes and GR co-regulators that are important for its anti-inflammatory effects in innate immune cells, as well as mutations within the GR itself that shed light on its transcriptional activity. This research progress will hopefully serve as the basis for the development of safer immune suppressants with reduced side effect profiles.
几十年来,糖皮质激素一直被广泛用作治疗炎症的金标准治疗方法。不幸的是,它们的临床应用受到严重不良反应的限制,如胰岛素抵抗、心血管代谢疾病、肌肉和皮肤萎缩、骨质疏松症和抑郁症。糖皮质激素通过与糖皮质激素受体(GR)结合发挥作用,GR 是一种配体激活的转录因子,可正向和负向调节基因表达。过去几年的广泛研究揭示了 GR 激活和抑制其靶基因的新机制。全基因组研究和小鼠模型为 GR 调节炎症基因的分子机制提供了有价值的见解。本综述重点介绍了新发现的靶基因和 GR 共调节剂,这些基因和调节剂对于其在先天免疫细胞中的抗炎作用很重要,以及 GR 自身的突变,这些突变揭示了其转录活性。希望这一研究进展将为开发具有更低副作用谱的更安全的免疫抑制剂奠定基础。